Biomica VP R&D to Present at the Pharmabiotics 2023 Conference on March 21, 2023
Biomica Ltd., a clinical-stage biopharmaceutical company and subsidiary of Evogene (NASDAQ: EVGN), announced that Dr. Shiri Meshner, VP of R&D, will present at the Pharmabiotics 2023 Conference in Lyon, France, on March 21-22, 2023.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Biomica Ltd., a clinical-stage biopharmaceutical company and subsidiary of Evogene (NASDAQ: EVGN), announced that Dr. Shiri Meshner, VP of R&D, will present at the Pharmabiotics 2023 Conference in Lyon, France, on March 21-22, 2023. Dr. Meshner's presentation, titled Biomica's BMC128 - a Rationally Designed LBP Consortium's Journey to the Clinic, will occur on March 21 at 3:40 PM CET. Biomica's proprietary BMC128, consisting of four live bacterial strains, showed significant tumor volume reduction and improved survival compared to anti-PD-1 therapy in preclinical studies. Currently, BMC128 is undergoing a Phase 1 trial (NCT05354102) in patients with non-small cell lung cancer, melanoma, and renal cell carcinoma.
Details
News Market Reaction – EVGN
The recorded move for EVGN in the trading session of this news was +0.41%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REHOVOT, Israel, March 15, 2023 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced that its VP R&D, Dr. Shiri Meshner, will be presenting at the Pharmabiotics 2023 Conference, 'The Future of Microbiome-based Medicines', taking place in Lyon, France from March 21-22, 2023.
Dr. Meshner will be presenting on March 21, at 3:40pm CET, in a presentation entitled, 'Biomica's BMC128 - a Rationally Designed LBP Consortium's Journey to the Clinic.'
Biomica's proprietary BMC128 is a rationally designed consortia of 4 live bacterial strains which demonstrated a significant reduction of cancer tumor volumes and increased survival in pre-clinical animal studies compared to anti-PD1 therapy alone.
BMC128 is currently being tested in a 12 patient Phase 1 open label study (ClinicalTrials.gov Identifier: NCT05354102) to primarily evaluate its safety and tolerability in combination with anti-PD-1 (Opdivo) in patients with either non-small cell lung cancer (NSCLC), melanoma or renal cell carcinoma (RCC), in patients whose cancers did not respond to treatment with an anti-PD-1 drug. The objectives in this Phase 1 trial will also explore efficacy variables.
Dr. Meshner will be available for one-on-one meetings with participants throughout the conference, and those interested should be in touch with her directly.
About Biomica Ltd.:
Biomica is a clinical stage biopharmaceutical company developing innovative microbiome-based therapeutics utilizing MicroBoost AI tech-engine, licensed from Evogene. Biomica aims to identify and characterize disease-related microbiome entities and to develop novel therapeutics based on these understandings. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. Biomica is a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN).
For more information about Biomica, please visit www.biomicamed.com.
About Evogene Ltd.:
Evogene (NASDAQ: EVGN) (TASE: EVGN) is a computational biology company aiming to revolutionize the development of life-science based products by utilizing cutting edge technologies to increase the probability of success while reducing development time and cost. Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI – leveraging Big Data and Artificial Intelligence and incorporating deep multidisciplinary understanding in life sciences. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).
Evogene uses its tech-engines to develop products through subsidiaries and strategic partnerships. Evogene's subsidiaries currently utilize the tech-engines to develop human microbiome-based therapeutics by Biomica, ag-biologicals by Lavie Bio, ag-chemicals by AgPlenus, medical cannabis products by Canonic and castor varieties, for the biofuel and other industries, by Casterra.
Investor Contact:
Kenny Green
Email: kenny.green@evogene.com
Tel: +1 212 378 8040
Dr. Shiri Meshner, PhD, VP of R&D
Email: shiri.meshner@biomicamed.com
Logo: https://mma.prnewswire.com/media/1974949/Biomica.jpg
Logo: https://mma.prnewswire.com/media/1947468/Evogene.jpg
View original content:https://www.prnewswire.com/news-releases/biomica-vp-rd-to-present-at-the-pharmabiotics-2023-conference-on-march-21-2023-301772684.html
SOURCE Biomica Ltd.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.